Which marker is typically expressed in high levels in diffuse large B-cell lymphoma?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the NBME Form 29 Test. Study with interactive flashcards and detailed multiple-choice questions, each with explanations and tips. Achieve success on your exam!

Multiple Choice

Which marker is typically expressed in high levels in diffuse large B-cell lymphoma?

Explanation:
Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma characterized by the rapid proliferation of large B-lymphoid cells. One of the hallmarks of this condition is the overexpression of the BCL2 protein. BCL2 is an anti-apoptotic protein that helps cells avoid programmed cell death, allowing malignant cells to survive longer than they normally would. In DLBCL, the overexpression of BCL2 occurs due to genetic alterations such as chromosomal translocations, particularly the t(14;18) translocation, which juxtaposes the BCL2 gene to the immunoglobulin locus. This dysregulation contributes to the pathogenesis of lymphoma by enabling the affected B cells to evade apoptosis, leading to their accumulation and the development of the disease. While markers like CD10, CD5, and BCL6 may be associated with other lymphomas or different subtypes of DLBCL, it is BCL2 that is notably associated with the aggressive nature and clinical implications in diffuse large B-cell lymphoma, making its expression a critical marker in the diagnosis and prognosis of this condition.

Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma characterized by the rapid proliferation of large B-lymphoid cells. One of the hallmarks of this condition is the overexpression of the BCL2 protein. BCL2 is an anti-apoptotic protein that helps cells avoid programmed cell death, allowing malignant cells to survive longer than they normally would.

In DLBCL, the overexpression of BCL2 occurs due to genetic alterations such as chromosomal translocations, particularly the t(14;18) translocation, which juxtaposes the BCL2 gene to the immunoglobulin locus. This dysregulation contributes to the pathogenesis of lymphoma by enabling the affected B cells to evade apoptosis, leading to their accumulation and the development of the disease.

While markers like CD10, CD5, and BCL6 may be associated with other lymphomas or different subtypes of DLBCL, it is BCL2 that is notably associated with the aggressive nature and clinical implications in diffuse large B-cell lymphoma, making its expression a critical marker in the diagnosis and prognosis of this condition.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy